Delving into the Latest Updates on Baxter Oncology GmbH with Synapse

Overview

Basic Info

Introduction

Baxter Oncology GmbH is a pharmaceutical corporation that specializes in the production of medications for cancer treatment, including chemotherapy and hormone therapy. This company, which is a part of Baxter International, Inc., is based in Halle, Germany and has been in operation since 1919.

Tags

Neoplasms

Skin and Musculoskeletal Diseases

Antibody drug conjugate (ADC)

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3
Nervous System Diseases	2
Endocrinology and Metabolic Disease	2
Hemic and Lymphatic Diseases	1
Immune System Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Antibody drug conjugate (ADC)	2
Small molecule drug	1

Top 5 Target	Count

Tubulin x nectin-4	1
Top I x Trop-2	1
DNA	1

[Translation] A phase III, open-label, sponsor-blinded, randomized study evaluating Dato-DXd with or without osimertinib versus platinum-based chemotherapy in participants with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer who have progressed on prior osimertinib (TROPION-Lung15)

本研究旨在评估 Dato-DXd 联合或不联合奥希替尼对比含铂化疗在既往奥希替尼治疗出现疾病进展的EGFRm 局部晚期或转移性 NSCLC 参与者中的疗效。拟定双主要研究终点旨在证明 Dato-DXd 联合和不联合奥希替尼在盲态独立中心审查（BICR）评估的 PFS 方面相较于化疗的优效性。关键次要有效性终点是OS和CNS PFS。还将评估 Dato-DXd 联合或不联合奥希替尼相较于化疗的安全性和耐受性特征。

[Translation]

This study is designed to evaluate Dato-DXd with or without osimertinib versus platinum-based chemotherapy in participants with EGFRm locally advanced or metastatic NSCLC who have progressed on prior osimertinib therapy. The proposed dual primary endpoints are to demonstrate the superiority of Dato-DXd with or without osimertinib versus chemotherapy with respect to PFS assessed by blinded independent central review (BICR). Key secondary efficacy endpoints are OS and CNS PFS. The safety and tolerability profile of Dato-DXd with or without osimertinib versus chemotherapy will also be evaluated.

Start Date05 Feb 2025

Sponsor / Collaborator

AstraZeneca AB

[+2]

CTR20244069

/ RecruitingPhase 3

一项评价帕博利珠单抗与透明质酸酶复方制剂（MK-3475A）皮下给药对比帕博利珠单抗静脉给药一线治疗PD-L1 TPS≥50%的转移性非小细胞肺癌受试者的药代动力学和安全性的III期、随机、开放临床研究

[Translation] A phase III, randomized, open-label clinical study to evaluate the pharmacokinetics and safety of subcutaneous administration of pembrolizumab and hyaluronidase combination (MK-3475A) versus intravenous administration of pembrolizumab as first-line treatment for patients with metastatic non-small cell lung cancer with PD-L1 TPS ≥ 50%

评估MK-3475A皮下给药与帕博利珠单抗静脉给药作为转移性非小细胞肺癌受试者一线治疗时的药代动力学和安全性

[Translation]

To evaluate the pharmacokinetics and safety of subcutaneous MK-3475A versus intravenous pembrolizumab as first-line treatment in subjects with metastatic non-small cell lung cancer

Start Date20 Dec 2024

Sponsor / Collaborator

MSD R&D (China) Co. Ltd.

[+2]

CTR20243775

/ RecruitingPhase 4

一项盐酸伊立替康脂质体（易安达®）联合5-氟尿嘧啶（5-FU）和亚叶酸（LV）治疗中国转移性胰腺癌患者的安全性和有效性作为批准条件的多中心、单臂、前瞻性非干预性研究（SEOPAC）

[Translation] A multicenter, single-arm, prospective, non-interventional study to investigate the safety and efficacy of liposomal irinotecan hydrochloride (Irinotecan®) in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in Chinese patients with metastatic pancreatic cancer as a condition of approval (SEOPAC)

主要目的：描述接受标准临床治疗的中国大陆转移性胰腺癌患者使用易安达®治疗的安全性。次要目的：描述接受标准临床治疗的中国大陆转移性胰腺癌患者使用易安达®联合5-FU和LV治疗的有效性。

[Translation]

Primary objective: To describe the safety of Eandra® in patients with metastatic pancreatic cancer in mainland China who received standard clinical treatment. Secondary objective: To describe the effectiveness of Eandra® combined with 5-FU and LV in patients with metastatic pancreatic cancer in mainland China who received standard clinical treatment.

Start Date10 Dec 2024

Sponsor / Collaborator

Les Laboratoires Servier SAS

[+3]

100 Clinical Results associated with Baxter Oncology GmbH

Login to view more data

0 Patents (Medical) associated with Baxter Oncology GmbH

Login to view more data

2

Literatures (Medical) associated with Baxter Oncology GmbH

01 Dec 2019·Journal of nanobiotechnology

Correction to: Binding mechanism of anti-cancer chemotherapeutic drug mitoxantrone to DNA characterized by magnetic tweezers

Author: Wang, Ying ; Toensing, Katja ; Rattay, Michael ; Anselmetti, Dario ; Kreft, Dennis

Following publication of this article [1] we found a typographical error in the results reported in the abstract. The corrected sentences should read as below.

01 Dec 2018·Journal of nanobiotechnologyQ2 · ENGINEERING & TECHNOLOGY

Binding mechanism of anti-cancer chemotherapeutic drug mitoxantrone to DNA characterized by magnetic tweezers

Q2 · ENGINEERING & TECHNOLOGY

ArticleOA

Author: Wang, Ying ; Toensing, Katja ; Rattay, Michael ; Anselmetti, Dario ; Kreft, Dennis

BACKGROUND:

Chemotherapeutic agents (anti-cancer drugs) are small cytostatic or cytotoxic molecules that often bind to double-stranded DNA (dsDNA) resulting in modifications of their structural and nanomechanical properties and thus interfering with the cell proliferation process.

METHODS:

We investigated the anthraquinone compound mitoxantrone that is used for treating certain cancer types like leukemia and lymphoma with magnetic tweezers as a single molecule nanosensor. In order to study the association of mitoxantrone with dsDNA, we conducted force-extension and mechanical overwinding experiments with a sensitivity of 10^-14 N.

RESULTS:

Using this method, we were able to estimate an equilibrium constant of association K_a ≈ 1 × 105 M^-1 as well as a binding site size of n ≈ 2.5 base pairs for mitoxantrone. An unwinding angle of mitoxantrone-intercalation of ϑ ≈ 16° was determined.

CONCLUSION:

Moreover, we observed a complex concentration-dependent bimodal binding behavior, where mitoxantrone associates to dsDNA as an intercalator and groove binder simultaneously at low concentrations and as a mere intercalator at high concentrations.

100 Deals associated with Baxter Oncology GmbH

Login to view more data

100 Translational Medicine associated with Baxter Oncology GmbH

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 20 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

NDA/BLA

3

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Enfortumab Vedotin-ejfv ( Tubulin x nectin-4 )	Locally Advanced Urothelial Carcinoma More	NDA/BLA
Datopotamab Deruxtecan ( Top I x Trop-2 )	Hormone receptor positive HER2 negative breast cancer More	NDA/BLA
Mafosfamide ( DNA )	Meningeal Carcinomatosis More	Discontinued
D-64131 ( Tubulin )	Neoplasms More	Pending
D-70166 ( HER2 exon 20 )	Breast Cancer More	Pending